{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T06:10:14Z","timestamp":1792131014010,"version":"4.4.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T00:00:00Z","timestamp":1773878400000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Federal Ministry of Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We previously conducted the TONE study (Treatment of optic neuritis with erythropoietin, NCT01962571), which analysed 103 patients with acute optic neuritis and no prior history of multiple sclerosis after randomization to receive high-dose erythropoietin or placebo as an adjunct to methylprednisolone pulse therapy. All visual system-related outcomes yielded negative results. The goal of the current investigation is to assess whether erythropoietin administration influenced inflammatory optic nerve and cerebral lesions or optic nerve atrophy on MRI. We determined the sensitivity of MRI in detecting optic nerve lesions and assessed the influence of the methylprednisolone treatment delay.<\/jats:p>\n                  <jats:p>In this ancillary analysis of MRI images that were acquired during the TONE trial, we determined the optic nerve cross-sectional area, the extent of optic nerve T2 and gadolinium-enhancing lesions, the number of T2 and gadolinium-enhancing juxtacortical, periventricular and infratentorial white matter lesions, and the fulfilment of radiological dissemination-in-space and dissemination-in-time (2017 McDonald criteria). Lesion changes were analysed by non-parametrical statistical methods (Wilcoxon rank sum test and chi-square test) and the time to the occurrence of any new cerebral lesion was analysed by a Cox proportional hazards model. The impact of the time to methylprednisolone treatment was investigated through stratified analyses with a median split.<\/jats:p>\n                  <jats:p>We obtained baseline MRI from 77\/103 patients (75%), six months\u2019 follow-up from 40\/103 patients (39%), and included 52\/103 patients (50%) in the time-to-event analysis. At baseline, gadolinium-enhancing optic nerve lesions were more frequent in the placebo compared to the erythropoietin group. Otherwise, baseline characteristics were balanced. We found no clinically meaningful or statistically significant differences between erythropoietin and placebo recipients in terms of lesion changes or optic atrophy. The sensitivity for detecting any optic nerve lesion was 82% at baseline and 85% at month 6. Outcomes were similar between patients whose methylprednisolone treatment was initiated early (&amp;lt;6 days) versus late (\u22656 days) after symptom onset.<\/jats:p>\n                  <jats:p>In conclusion, this study provides class II evidence that high-dose erythropoietin in conjunction with methylprednisolone has no effect on the evolution of optic nerve or cerebral white matter lesions in patients presenting with acute optic neuritis.<\/jats:p>","DOI":"10.1093\/braincomms\/fcag082","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T12:51:00Z","timestamp":1773838260000},"source":"Crossref","is-referenced-by-count":1,"title":["Treatment of optic neuritis with erythropoietin: impact on white matter and optic nerve MRI characteristics"],"prefix":"10.1093","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0758-5120","authenticated-orcid":false,"given":"Sebastian","family":"K\u00fcchlin","sequence":"first","affiliation":[{"name":"Eye Center, Medical Center\u2014University of Freiburg, Faculty of Medicine, University of Freiburg , D-79106 Freiburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"L\u00fctzen","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Medical Center\u2014University of Freiburg, Faculty of Medicine, University of Freiburg , D-79106 Freiburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Farassat","sequence":"additional","affiliation":[{"name":"Eye Center, Medical Center\u2014University of Freiburg, Faculty of Medicine, University of Freiburg , D-79106 Freiburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricarda","family":"Diem","sequence":"additional","affiliation":[{"name":"Department of Neurology and National Center for Tumor Diseases, Faculty of Medicine, University Hospital Heidelberg , D-69120 Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7987-658X","authenticated-orcid":false,"given":"Philipp","family":"Albrecht","sequence":"additional","affiliation":[{"name":"Department of Neurology, Maria Hilf Clinics M\u00f6nchengladbach , D-41063 M\u00f6nchengladbach ,","place":["Germany"]},{"name":"Department of Neurology, Medical Faculty, Heinrich Heine-Universit\u00e4t D\u00fcsseldorf , D-40225 D\u00fcsseldorf ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan","family":"Aktas","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical Faculty, Heinrich Heine-Universit\u00e4t D\u00fcsseldorf , D-40225 D\u00fcsseldorf ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Heesen","sequence":"additional","affiliation":[{"name":"Institute of Neuroimmunology and Multiple Sclerosis and Department of Neurology, University Medical Center Hamburg-Eppendorf , D-20246 Hamburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amelie","family":"Pielen","sequence":"additional","affiliation":[{"name":"Maximilians-Augenklinik GmbH, D-90491 N\u00fcrnberg, and University Clinic for Ophthalmology, Hannover Medical School , D-30625 Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Horst","family":"Urbach","sequence":"additional","affiliation":[{"name":"Department of Neuroradiology, Medical Center\u2014University of Freiburg, Faculty of Medicine, University of Freiburg , D-79106 Freiburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin J","family":"Hug","sequence":"additional","affiliation":[{"name":"Pharmacy, Medical Center\u2014University of Freiburg, Faculty of Medicine, University of Freiburg , D-79106 Freiburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt-Wolfram","family":"S\u00fchs","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hannover Medical School , D-30625 Hannover ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf A","family":"Lagr\u00e8ze","sequence":"additional","affiliation":[{"name":"Eye Center, Medical Center\u2014University of Freiburg, Faculty of Medicine, University of Freiburg , D-79106 Freiburg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,19]]},"reference":[{"issue":"1","key":"2026041706212830800_fcag082-B1","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","article-title":"Optic neuritis","volume":"13","author":"Toosy","year":"2014","journal-title":"Lancet Neurol"},{"issue":"2","key":"2026041706212830800_fcag082-B2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1001\/jamaneurol.2019.3283","article-title":"Using acute optic neuritis trials to assess neuroprotective and remyelinating therapies in multiple sclerosis","volume":"77","author":"Andorr\u00e0","year":"2020","journal-title":"JAMA Neurol"},{"issue":"9","key":"2026041706212830800_fcag082-B3","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199202273260901","article-title":"A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis","volume":"326","author":"Beck","year":"1992","journal-title":"N Engl J Med"},{"key":"2026041706212830800_fcag082-B4","first-page":"CD001430","article-title":"Corticosteroids for treating optic neuritis. Cochrane eyes and vision group, ed","volume":"2015","author":"Gal","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"2026041706212830800_fcag082-B5","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.amjms.2016.10.009","article-title":"Erythropoietin and nonhematopoietic effects","volume":"353","author":"Nekoui","year":"2017","journal-title":"Am J Med Sci"},{"issue":"2","key":"2026041706212830800_fcag082-B6","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1002\/ana.23573","article-title":"A randomized, double-blind, phase 2 study of erythropoietin in optic neuritis","volume":"72","author":"S\u00fchs","year":"2012","journal-title":"Ann Neurol"},{"issue":"10","key":"2026041706212830800_fcag082-B7","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.3390\/ijms17101666","article-title":"Disease activity and conversion into multiple sclerosis after optic neuritis is treated with erythropoietin","volume":"17","author":"S\u00fchs","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2026041706212830800_fcag082-B8","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S1474-4422(21)00322-7","article-title":"Safety and efficacy of erythropoietin for the treatment of patients with optic neuritis (TONE): A randomised, double-blind, multicentre, placebo-controlled study","volume":"20","author":"Lagr\u00e8ze","year":"2021","journal-title":"Lancet Neurol"},{"issue":"4","key":"2026041706212830800_fcag082-B9","doi-asserted-by":"crossref","first-page":"e200067","DOI":"10.1212\/NXI.0000000000200067","article-title":"Treatment with erythropoietin for patients with optic neuritis: Long-term follow-up","volume":"10","author":"K\u00fcchlin","year":"2023","journal-title":"Neurol\u2014Neuroimmunol Neuroinflammation"},{"key":"2026041706212830800_fcag082-B10","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.brainres.2017.08.012","article-title":"Time is vision in recurrent optic neuritis","volume":"1673","author":"Osinga","year":"2017","journal-title":"Brain Res"},{"issue":"3","key":"2026041706212830800_fcag082-B11","doi-asserted-by":"crossref","first-page":"e010956","DOI":"10.1136\/bmjopen-2015-010956","article-title":"Treatment of optic neuritis with erythropoietin (TONE): A randomised, double-blind, placebo-controlled trial\u2014Study protocol","volume":"6","author":"Diem","year":"2016","journal-title":"BMJ Open"},{"issue":"2","key":"2026041706212830800_fcag082-B12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"9596","key":"2026041706212830800_fcag082-B13","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The strengthening the reporting of observational studies in epidemiology (STROBE) statement: Guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"The Lancet"},{"issue":"8","key":"2026041706212830800_fcag082-B14","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1007\/s00415-004-0477-1","article-title":"Visual recovery following acute optic neuritis: A clinical, electrophysiological and magnetic resonance imaging study","volume":"251","author":"Hickman","year":"2004","journal-title":"J Neurol"},{"issue":"1","key":"2026041706212830800_fcag082-B15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/jnnp-2019-321653","article-title":"Case for a new corticosteroid treatment trial in optic neuritis: Review of updated evidence","volume":"91","author":"Petzold","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2026041706212830800_fcag082-B16","doi-asserted-by":"crossref","first-page":"1102353","DOI":"10.3389\/fneur.2023.1102353","article-title":"The acute optic neuritis network (ACON): Study protocol of a non-interventional prospective multicenter study on diagnosis and treatment of acute optic neuritis","volume":"14","author":"Asseyer","year":"2023","journal-title":"Front Neurol"},{"issue":"10","key":"2026041706212830800_fcag082-B17","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/S1474-4422(25)00270-4","article-title":"Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria","volume":"24","author":"Montalban","year":"2025","journal-title":"Lancet Neurol"},{"issue":"1","key":"2026041706212830800_fcag082-B18","doi-asserted-by":"crossref","first-page":"e200805","DOI":"10.1212\/WNL.0000000000207805","article-title":"Adding the optic nerve in multiple sclerosis diagnostic criteria: A longitudinal, prospective, multicenter study","volume":"102","author":"Vidal-Jordana","year":"2024","journal-title":"Neurology"},{"issue":"2","key":"2026041706212830800_fcag082-B19","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.jcjo.2018.05.013","article-title":"Sensitivity of orbital magnetic resonance imaging in acute demyelinating optic neuritis","volume":"54","author":"Bursztyn","year":"2019","journal-title":"Can J Ophthalmol"}],"container-title":["Brain Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/braincomms\/advance-article-pdf\/doi\/10.1093\/braincomms\/fcag082\/67417499\/fcag082.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/2\/fcag082\/67417499\/fcag082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/braincomms\/article-pdf\/8\/2\/fcag082\/67417499\/fcag082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:21:36Z","timestamp":1776421296000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/braincomms\/article\/doi\/10.1093\/braincomms\/fcag082\/8529280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3,3]]}},"URL":"https:\/\/doi.org\/10.1093\/braincomms\/fcag082","relation":{},"ISSN":["2632-1297"],"issn-type":[{"value":"2632-1297","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"fcag082"}}